Top
New International Commission Launched on Clinical Use of Heritable Human Genome Editing - Healing Genes
1059
post-template-default,single,single-post,postid-1059,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2078

New International Commission Launched on Clinical Use of Heritable Human Genome Editing

Share on facebook
Share on google
Share on twitter
Share on linkedin

An international commission has been convened by the U.S. National Academy of Medicine (NAM), the U.S. National Academy of Sciences (NAS), and the Royal Society of the U.K., with the participation of science and medical academies around the world, to develop a framework for scientists, clinicians, and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing. The framework will identify a number of scientific, medical, and ethical requirements that should be considered, and could inform the development of a potential pathway from research to clinical use — if society concludes that heritable human genome editing applications are acceptable.

Read the full story here: http://nas.edu/gene-editing/international-commission/index.htm?utm_source=Human+Genome+Editing+Initiative&utm_campaign=dcb86355f1-EMAIL_CAMPAIGN_2019_05_21_07_05&utm_medium=email&utm_term=0_a2539fe65c-dcb86355f1-278835489&mc_cid=dcb86355f1&mc_eid=2598e127a0

More to explorer

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader

CRISPR treatment inserted directly into the body for first time

A person with a genetic condition that causes blindness has become the first to receive a CRISPR–Cas9 gene therapy administered directly into their body. The treatment is part of a landmark clinical trial to test the ability of CRISPR–Cas9 gene-editing techniques to remove mutations that

No Comments

Sorry, the comment form is closed at this time.